About
Contact
Subscribe
e-Edition

Make Home Page

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

- Site search

Home
News
Sports
- Local Sports
- National Sports
Business
Opinion
A & E
Life
Features & Magazines
Classifieds
Weather
Obituaries
Parcel Pickup

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

EyePoint, Inc. - Common Stock (NQ:EYPT)

14.13 +0.56 (+4.13%)

Streaming Delayed Price Updated: 1:04 PM EDT, Apr 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about EyePoint, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Bragar Eagel & Squire, P.C. Is Investigating GrafTech, BRP, Cantaloupe, and EyePoint and Encourages Investors to Contact the Firm

December 12, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating GrafTech, BRP, Cantaloupe, and EyePoint and Encourages Investors to Contact the Firm

December 02, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating EyePoint, F45, PROG, and Establishment and Encourages Investors to Contact the Firm

November 21, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Wednesday ↗

November 30, 2022

During Wednesday's session, 107 stocks hit new 52-week lows.

Via Benzinga

AiViva Reports That Their Promising New Treatment For Wet AMD Is Soon To Be Ready For Clinical Trials ↗

November 14, 2022

Visit https://www.startengine.com/aiviva to invest in AiViva’s StartEngine Campaign.

Via Benzinga

Bragar Eagel & Squire, P.C. Is Investigating EyePoint, F45, PROG, and Intuit and Encourages Investors to Contact the Firm

November 11, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Cantaloupe, EyePoint, Spectrum, and F45 Training and Encourages Investors to Contact the Firm

November 06, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

NASDAQ:EYPT Investor Alert: Investigation over Potential Securities Laws Violations by EyePoint Pharmaceuticals, Inc. ↗

November 02, 2022

San Diego, CA -- (SBWIRE) -- 11/02/2022 -- EyePoint Pharmaceuticals, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

EyePoint Pharmaceuticals: Q3 Earnings Insights ↗

November 02, 2022

EyePoint Pharmaceuticals (NASDAQ:EYPT) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Bragar Eagel & Squire, P.C. Is Investigating Vintage Wine, Flowserve, Cantaloupe, and EyePoint and Encourages Investors to Contact the Firm

October 31, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating FedEx, Cantaloupe, Compass, and EyePoint and Encourages Investors to Contact the Firm

October 27, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Cantaloupe, EyePoint, F45 Training, and PROG and Encourages Investors to Contact the Firm

October 26, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, F45, and PROG and Encourages Investors to Contact the Firm

October 16, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, and F45 and Encourages Investors to Contact the Firm

October 11, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Compass, EyePoint, F45, and PROG and Encourages Investors to Contact the Firm

October 06, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Meet The Company Bringing New Treatments For Serious Eye Issues To Market ↗

October 05, 2022

Via Benzinga

EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm

August 31, 2022

From Bragar Eagel & Squire, P.C.

Via Business Wire

Stocks That Hit 52-Week Lows On Wednesday ↗

October 05, 2022

Wednesday saw 127 companies set new 52-week lows.

Via Benzinga

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors

August 31, 2022

From Glancy Prongay & Murray LLP

Via Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

August 31, 2022

From The Schall Law Firm

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors

August 31, 2022

From Law Offices of Howard G. Smith

Via Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors

August 30, 2022

From The Law Offices of Frank R. Cruz

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

August 30, 2022

From The Schall Law Firm

Via Business Wire

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗

August 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap: EyePoint Pharmaceuticals Q2 Earnings ↗

August 03, 2022

EyePoint Pharmaceuticals (NASDAQ:EYPT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Preview For EyePoint Pharmaceuticals ↗

August 02, 2022

EyePoint Pharmaceuticals (NASDAQ:EYPT) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Recap of Monday's Biotech Catalysts - End of the Day Summary ↗

July 18, 2022

Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 15, 2022

Via Benzinga

EyePoint Announces Positive Safety and Efficacy Data From Initial-Stage Wet AMD Study ↗

July 15, 2022

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced 12-month data readout from the Phase 1 DAVIO clinical trial evaluating EYP-1901, targeting wet age-related macular degeneration (wet AMD) as a...

Via Benzinga

Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday ↗

July 18, 2022

Gainers United Maritime Corporation (NASDAQ: USEA) shares climbed 175.9% to close at $6.07 on Friday. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Opinion
Photo Galleries
Videos
Local Events
Classifieds
Obituaries

Services

About
Contact
Personnel
Advertise
Subscription Services
Promote Your Event
Dealer Locations
Email Alerts
Submission Forms

Contact Information

chroniclejournal.com
75 S. Cumberland Street
Thunder Bay, ON P7B 1A3
Phone: 807 343 6200
Email: circulation@chroniclejournal.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

EyePoint, Inc. - Common Stock (NQ:EYPT)

All News about EyePoint, Inc. - Common Stock

Sections

Services

Contact Information

Follow Us